GenVec (GNVC) – StreetInsider.com Reports
-
MaxCyte, Inc. (MXCT) Appoints Douglas Swirsky as CFO
-
Rodman & Renshaw Downgrades GenVec, Inc. (GNVC) to Neutral
-
Intrexon (XON) to Acquire GenVec (GNVC)
-
GenVec (GNVC) Halted, News Pending
-
Pre-Open Stock Movers 01/10: (GNVC) (ILMN) (VRX) Higher; (ASNA) (WMB) (FRSH) Lower (more...)
-
GenVec (GNVC) Adds to Gains in Pre-Open Trade
-
GenVec (GNVC) Surges Into the Close; Reason Unknown
-
GenVec (GNVC) halted again LUDP last up 20%
-
GenVec (GNVC) halted again LUDP last up 30%
-
GenVec (GNVC) halted on LUDP, last up 9.2%
-
GenVec (GNVC) Announces Effectiveness of One-for-Ten Reverse Stock Split
-
GenVec (GNVC) Files 4.5M Common Shelf for Selling Stockholders
-
GenVec (GNVC) Says Novartis (NVS) Remains Committed to CGF166 Amid Internal Changes
-
GenVec (GNVC) Tops Q1 EPS by 4c
-
Roth Capital Trims PT on GenVec (GNVC) to $2 Following CGF166 Clinical Hold Lift
-
Pre-Open Stock Movers 07/25: (GNVC) (OUTR) (S) Higher; (SC) (WAB) (ROP) Lower (more...)
-
GenVec (GNVC) Says FDA Clinical Hold on CGF166 Phase 1/2 Lifted
-
GenVec (GNVC) Enters $5M ATM Offering
-
GenVec (GNVC) Updates on CGF166 Phase 1/2; DSMB Recommends Trial Continue, Subject to Approval (NVS)
-
GenVec (GNVC) Misses Q4 EPS by 2c
-
Trading Radar for 3/9: Square (SQ), Express (EXPR), Vera Bradley (VRA), Box (BOX) Report
-
GenVec (GNVC) Updates on Recent Developments; Still Waiting for Guidance on CGF166 Study
-
Unusual 11 Mid-Day Movers 1/11: (ATV) (AFFX) (KONA) Higher; (GNVC) (TMST) (BTU) Lower
-
GenVec (GNVC) Misses Q2 EPS by 1c
-
GenVec (GNVC) FY14 Results Flat with Views; Hearing Loss Phase I Update Encouraging - Roth Capital
-
GenVec (GNVC) Tops Q4 EPS by 3c
-
Trading Radar for 3/24: McCormick (MKC), GenVec (GNVC), Steelcase (SCS), Christopher & Banks (CBK) Report
-
GenVec (GNVC), TheraBiologics Enter Collaboration for Cancer Therapeutics Technology Development
-
2015 Could be 'Potentially Transformative' Year for GenVec (GNVC); Roth Affirms at 'Buy'
-
GenVec (GNVC) Hits Session Highs on Volume
-
GenVec (GNVC) Tops Q3 EPS by 1c
-
Roth Affirms GenVec (GNVC) at 'Buy'; Novartis Partnership is Entering 'Prime Time'
-
GenVec (GNVC) Reports Dosing in Novartis (NVS) Phase 1/2 Using Bilateral Hearing Loss Treatment Tech
-
GenVec (GNVC) Director Horovitz to Retire
-
GenVec, Inc. New (GNVC) Tops Q2 EPS by 5c
-
GenVec, Inc. New (GNVC) Posts Q1 Loss of 7c/Share
-
GenVec, Inc. New (GNVC) Narrows Q4 Loss on Lighter Revs; Guides FY14 Cash Burn
-
Cormorant Asset Management, LLC Shows New 7.7% Stake in GenVec (GNVC)
-
GenVec (GNVC) to Place $9M of Common at $3.15/Share
-
H.C. Wainwright Starts GenVec, Inc. (GNVC) at Buy
-
Roth Capital Resumes GenVec (GNVC) at Buy; Novartis (NVS) Program Reinvigorates Excitement
-
GenVec (GNVC) Files $75M Mixed Shelf
-
Notable 52-Week Highs and Lows of the Day 12/12: (GNVC) (CYTR) (CORT) High; (IMUC) (SYN) (IAG) Low
-
Unusual 11 Mid-Day Movers 12/12: (GNVC) (NLP) (ZN) Higher; (IMUC) (SPPR) (SYN) Lower
-
GenVec (GNVC) Rips Higher After Phase 1 study of CGF166 Approved; IND Expected Early Next year
-
GenVec, Inc. New (GNVC) Narrows Q3 Loss
-
GenVec (GNVC) Regains Compliance for Continued Nasdaq Listing
-
Unusual 11 Mid-Day Movers 10/02: (GNVC) (FONR) (ZGNX) Higher; (STEM) (GTXI) (RECN) Lower
-
Unusual 11 Mid-Day Movers 09/24: (DQ) (GNVC) (ACUR) Higher; (CY) (BIOS) (RHT) Lower
-
GenVec (GNVC) Appoints Stefan F. Loren, Ph.D., to Board
Back to GNVC Stock Lookup